*Quotes on stock price are delayed and not real-time.
Curative Biotechnology, Inc., formerly Connectyx, a
development-stage biomedical company, focuses on novel treatments for
rare diseases. The company focuses on therapies with potentially
accelerated development paths as a result of the disease, the nature of
the therapeutic itself, or the stage of clinical development. Its pipeline
candidates include CUBT906, an antibody drug conjugate for targeting
CD56 positive brain tumors; and IMT504, a novel immune therapy to treat
rabies. Curative Biotechnology, Inc. was founded in 1995 and is based in
Boca Raton, Florida.